MaxCyte posts Q2 2026 revenue, reiterates full-year guidance

MaxCyte reported total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue¹. The company said its results were driven by execution on instrument placements and stability in processing assembly sales¹, according to CEO Maher Masoud.

Masoud pointed to a new development in the company's licensing business, saying MaxCyte had recently signed its first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech, which the company said would create new opportunities¹. That agreement was announced after the quarter closed, in July, per the filing's highlights.

On the SPL pipeline, the company disclosed that as of June 30, 2026, it had 29 total SPL agreements, with 12 programs having at least a cleared IND or equivalent status, and one program already commercial¹.

MaxCyte reiterated its full-year 2026 guidance, projecting total revenue of $30 million to $32 million, made up of $25 million to $27 million in core revenue and approximately $5 million in SPL-related revenue, split between about $3 million from milestone payments and about $2 million from commercial royalties¹.

On cash, the company stated total cash, cash equivalents and investments were $141.9 million as of June 30, 2026, and that it expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, not counting any additional funds used for the share repurchase program¹.

The company also noted it had repurchased approximately $5.5 million of common stock to date under its $10 million share repurchase program authorized by the Board¹.